An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

As one of the major therapeutic options for cancer treatment, chemotherapy has limited
selectivity against cancer cells. Consequently, this therapeutic strategy offers a small …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past
30 years. Clinical success rates of antibodies have exceeded expectations, resulting in …

Cancer and autoimmune disease are closely related, and many therapeutic antibodies are
widely used in clinics for the treatment of both diseases. Among them, the anti-CD20 …

Engineering approaches using antibody drug conjugates (ADCs) and bispecific antibodies
(bsAbs) are designed to overcome the limitations of conventional chemotherapies and …

With a number of antibody–drug conjugates (ADCs) approved for clinical use as targeted
cancer therapies and numerous candidates in clinical trials, the field of ADCs is emerging as …

The gem-dimethyl moiety is a structural feature frequently found in many natural products of
clinical interest, including, but not limited to, taxanes, epothilones, statins, retinoids, di …